Nova Measuring Instruments Ltd. - Ordinary Shares (NVMI) News

Nova Measuring Instruments Ltd. - Ordinary Shares (NVMI): $92.93

-2.89 (-3.02%)

POWR Rating

Component Grades













Filter NVMI News Items

NVMI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVMI News Highlights

  • For NVMI, its 30 day story count is now at 10.
  • Over the past 15 days, the trend for NVMI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about NVMI are NOVA, EYE and OPT.

Latest NVMI News From Around the Web

Below are the latest news stories about Nova Ltd that investors may wish to consider to help them evaluate NVMI as an investment opportunity.

Nova Reports Fourth Quarter and Full Year 2021 Results

Nova (Nasdaq: NVMI) today announced financial results for the fourth quarter and full year 2021.

Yahoo | February 24, 2022

Nova Expands Presence in China with New Office in Shanghai

Nova (Nasdaq: NVMI) today announced the establishment of its new Chinese local corporate entity and the opening of a new Chinese headquarters in Shanghai. Nova's business in China has grown significantly in recent years, serving the expansion of the regional semiconductor industry. The new facility is part of Nova's strategy to strengthen its global sites to tighten customers' partnerships and support company's continued expansion in the region.

Yahoo | February 23, 2022

What's in Store for Nova Measuring Instruments (NVMI) Q4 Earnings?

Nova Measuring Instruments (NVMI) fourth-quarter 2021 performance is likely to have benefited from the robust demand of its expanding product portfolio across all main product lines.

Yahoo | February 22, 2022

Nova Introduces Unique Portfolio to Address Next-Generation Logic Fabrication Challenges

Nova (Nasdaq: NVMI) announced today its metrology portfolio for advanced gate-all-around (GAA). To enhance its market-leading portfolio, the Company is unveiling multiple advanced solutions uniquely equipped to address the manufacturing challenges of next-generation logic devices.

Yahoo | February 17, 2022

This Small-Cap Stock Is Growing Revenues 43% Year-Over-Year. But Will Future Returns Measure Up?

The stock market has gotten off to a rough start in 2022. Growth stocks -- and tech stocks in particular -- have underperformed. The VanEck Vectors Semiconductor ETF (NASDAQ: SMH) has pulled back 13.9% in 2022 after bagging a 41.9% return in 2021.

Yahoo | February 16, 2022

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis®), compared to ranibizumab alone +6.7 letters comparative superiority of 2 mg OPT-302 combination therapy (p = 0.0253) in patients with PCV – a subtype of AMD, prevalent among Asian populations with high unmet medical need MELBOURNE, Australia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Opthea L

Yahoo | February 14, 2022

Opthea To Present at SVB Leerink Global Healthcare Conference

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. The presentation will be available beginning Thursday, February 1

Yahoo | February 10, 2022

ancosys Chemical Metrology Solution Selected by Additional Front-End Customer

Nova (Nasdaq: NVMI) announced today that ancosys' chemical-metrology solution was recently selected by an additional front-end wafer fabrication customer. To date, ancosys' ancolyzer® has been selected by five leading front-end wafer manufacturers, including a world-leading foundry. The newest selection of ancosys' chemical metrology solutions by leading customers indicates the significant growth in ancosys' front-end business.

Yahoo | February 9, 2022

Is Nova (NASDAQ:NVMI) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | February 9, 2022

Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022. Professor Gemmy Cheung will present data from patients with polypoidal choroidal vasculo

Yahoo | February 9, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4735 seconds.